Listed

Celularity Inc: Form 10-Q for the period ended Jun 30, 2022

Filed with the SEC on Aug 9, 2022 and accepted by EDGAR at Aug 9, 2022, 16:31 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2022-04-01 to 2022-06-30$3.8mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2022-01-01 to 2022-06-30$9.7mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Gross profit3 months2022-04-01 to 2022-06-30$597.0kus-gaap:GrossProfit
Gross profit6 months2022-01-01 to 2022-06-30$2.5mus-gaap:GrossProfit
Research and development3 months2022-04-01 to 2022-06-30$25.3mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2022-01-01 to 2022-06-30$47.0mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2022-04-01 to 2022-06-30$15.6mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2022-01-01 to 2022-06-30$32.0mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2022-04-01 to 2022-06-30$4.2mus-gaap:OperatingIncomeLoss
Operating income6 months2022-01-01 to 2022-06-30−$37.4mus-gaap:OperatingIncomeLoss
Income tax3 months2022-04-01 to 2022-06-30$17.0kus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2022-01-01 to 2022-06-30$17.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2022-04-01 to 2022-06-30$47.8mus-gaap:NetIncomeLoss
Net income6 months2022-01-01 to 2022-06-30−$15.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2022-04-01 to 2022-06-30$0.32us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2022-01-01 to 2022-06-30−$0.11us-gaap:EarningsPerShareDiluted
Basic EPS3 months2022-04-01 to 2022-06-30$0.34us-gaap:EarningsPerShareBasic
Basic EPS6 months2022-01-01 to 2022-06-30−$0.11us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2022-04-01 to 2022-06-30151,311,780 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2022-01-01 to 2022-06-30135,302,472 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2022-01-01 to 2022-06-30−$70.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2022-01-01 to 2022-06-30$2.9mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2022-06-30$38.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-06-30$75.5mus-gaap:AssetsCurrent
Total assetsAt period end2022-06-30$429.3mus-gaap:Assets
Current liabilitiesAt period end2022-06-30$32.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-06-30$279.2mus-gaap:Liabilities
Shareholders' equityAt period end2022-06-30$150.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-22-028775. Last ingested by Listed: Nov 11, 2026, 02:51 ET. Listed shows no prices and gives no investment advice.